SCHEMBL26265751

SCHEMBL26265751

CC(C)(C)c1cc2nc(C(F)(F)F)ccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
POLB P06746 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 6/20 0.35
HPGD P15428 3/20 0.35
KIF11 P52732 1/20 0.33
BRD4 O60885 1/20 0.33
ALDH1A1 P00352 5/20 0.33
LMNA P02545 1/20 0.33
PABPC1 P11940 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
KHK P50053 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19663767 0.88 ALDH1A1 (0.35) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL26423009 0.83 BRD4 (0.41) MAPTPOLBNPSR1MEN1KMT2A
SCHEMBL26262609 0.79 ALDH1A1 (0.34) MAPTPOLBNPSR1MEN1KMT2A
SCHEMBL26262624 0.77 CYP1A2 (0.38) MAPTPOLBMEN1KMT2ANPC1
SCHEMBL4249233 0.76 BACE1 (0.38) MEN1KMT2AALDH1A1LMNA
SCHEMBL4248284 0.76 SIRT2 (0.37) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL26262615 0.76 LMNA (0.34) KDM4EALDH1A1LMNAHSD17B10
SCHEMBL17907902 0.75 NPC1 (0.39) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL17907900 0.74 TP53 (0.33) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL17907901 0.73 MEN1 (0.39) POLBMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 MAPT 32/4885POLB 624/4885NPSR1 2061/4885
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME HCCS, HAVCR2, HDGF MAPT 3938/4885POLB 395/4885NPSR1 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.